Status:
COMPLETED
PHA-739358 for Treatment of Hormone Refractory Prostate Cancer
Lead Sponsor:
Nerviano Medical Sciences
Conditions:
Metastatic Hormone Refractory Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
To assess the antitumor activity of PHA-739358 administered as IV infusion according to two different dose schedules in metastatic HRPC patients progressing on standard, docetaxel-based 1st-line chemo...
Eligibility Criteria
Inclusion
- Metastatic hormone refractory prostate cancer progressing after docetaxel based therapy
- Adequate bone marrow, liver and kidney function
Exclusion
- More than one prior chemotherapy line
- Uncontrolled hypertension
- Brain or leptomeningeal disease
- Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure, cerebrovascular accident in the previous 6 months
Key Trial Info
Start Date :
September 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
118 Patients enrolled
Trial Details
Trial ID
NCT00766324
Start Date
September 1 2007
End Date
April 1 2011
Last Update
May 28 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nerviano Medical Sciences. Clinical Research Dept.
Nerviano, Milano, Italy, 20014